FDA Approval in NSCLC, Priority Review in Bladder Cancer, MBCC Highlights, and More

Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.

Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery

Ruxolitinib 1.5% cream outperformed placebo vehicle in reducing lesional skin involvement in patients with epidermal or superficially sclerotic cutaneous chronic GVHD.

Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.

Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.

Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.

The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.

The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.